2016 White Paper on Recent Issues in Bioanalysis: Focus on Biomarker Assay Validation (BAV) (Part 1 – Small Molecules, Peptides and Small Molecule Biomarkers by LCMS)

References

• Savoie N , BoothBP, BradleyTet al. 2008 White Paper: The 2nd Calibration and Validation Group Workshop on recent issues in good laboratory practice bioanalysis. Bioanalysis1 (1), 19–30 (2009).
   PubMed Web of Science ®Google Scholar
• Savoie N , GarofoloF, van AmsterdamPet al. 2009 White Paper on recent issues in regulated bioanalysis from the 3rd Calibration and Validation Group workshop. Bioanalysis2 (1), 53–68 (2010).
   PubMed Web of Science ®Google Scholar
• Savoie N , GarofoloF, van AmsterdamPet al. 2010 White Paper on recent issues in regulated bioanalysis and global harmonization of bioanalytical guidance. Bioanalysis2 (12), 1945–1960 (2010).
   PubMed Web of Science ®Google Scholar
• Garofolo F , RocciM, DumontIet al. 2011 White Paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis3 (18), 2081–2096 (2011).
   PubMed Web of Science ®Google Scholar
• DeSilva B , GarofoloF, RocciMet al. 2012 White Paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis4 (18), 2213–2226 (2012).
   PubMed Web of Science ®Google Scholar
• Stevenson L , RocciM, GarofoloFet al. 2013 White Paper on recent issues in bioanalysis: “hybrid” – the best of LBA & LC/MS. Bioanalysis5 (23), 2903–2918 (2013).
   PubMed Web of Science ®Google Scholar
• Fluhler E , HayesR, GarofoloFet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1 – small molecules by LCMS). Bioanalysis6 (22), 3039–3049 (2014).
   PubMed Web of Science ®Google Scholar
• Dufield D , NeubertH, GarofoloFet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 – hybrid LBA/LCMS, ELN & regulatory agencies’ input). Bioanalysis6 (23), 3237–3249 (2014).
   PubMed Web of Science ®Google Scholar
• Stevenson L , AmaravadiL, MylerHet al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 – LBA and immunogenicity). Bioanalysis6 (24), 3355–3368 (2014).
   PubMed Web of Science ®Google Scholar
• Welink J , FluhlerE, HughesNet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1 – small molecules by LCMS). Bioanalysis7 (22), 2913–2925 (2015).
   PubMed Web of Science ®Google Scholar
• Ackermann B , NeubertH, HughesNet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 – hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis7 (23), 3019–3034 (2015).
   PubMed Web of Science ®Google Scholar
• Amaravadi L , SongA, MylerHet al. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3 – LBA, biomarkers and immunogenicity). Bioanalysis7 (24), 3107–3124 (2015).
   PubMed Web of Science ®Google Scholar
• Li W , CohenLH. Quantitation of endogenous analytes in biofluid without a true blank matrix. Anal. Chem. 75 (21), 5854–5859 (2003).
   PubMed Web of Science ®Google Scholar
• Jones BR , SchultzGA, EcksteinJA, AckermannBL. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis4 (19), 2343–2356 (2012).
   PubMed Web of Science ®Google Scholar
• Zheng JJ , ShieldsEE, SnowKJet al. The utility of stable isotope labeled (SIL) analogues in the bioanalysis of endogenous compounds by LC–MS applied to the study of bile acids in a metabolomics assay. Anal. Biochem. 503, 71–78 (2016).
   PubMed Web of Science ®Google Scholar
• ICH S3A Guideline: note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies questions and answers (2016).
   Google Scholar
• Denniff P , ParryS, DopsonW, SpoonerN. J. Pharm. Biomed. Anal. 108, 61–69 (2015).
   PubMed Web of Science ®Google Scholar
• Ciccimaro E , RanasingheA, D’ArienzoCet al. Strategy to improve the quantitative LC–MS analysis of molecular ions resistant to gas-phase collision induced dissociation: application to disulfide-rich cyclic peptides. Anal. Chem. 86 (23), 11523–11527 (2014).
   PubMed Web of Science ®Google Scholar
• Boulieu R , BleyzacN, FerryS. Modified high-performance liquid chromatographic method for the determination of ganciclovir in plasma from patients with severe renal impairment. J. Chromatogr. 571 (1–2), 331–333 (1991).
   PubMed Web of Science ®Google Scholar
• Anderson MDG , BreidingerSA, WoolfEJ. Effect of disease state on ionization during bioanalysis of MK-7009, a selective HCV NS3/NS4 protease inhibitor, in human plasma and human Tween-treated urine by high-performance liquid chromatography with tandem mass spectrometric detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877 (11–12), 1047–1056 (2009).
   PubMed Web of Science ®Google Scholar
• Xu Y , ProhnM, CaiXet al. Direct comparison of radioimmunoassay and LC–MS/MS for PK assessment of insulin glargine in clinical development. Bioanalysis6 (24), 3311–3323 (2014).
   PubMed Web of Science ®Google Scholar
• Vaught J . Blood collection, shipment, processing, and storage. Cancer Epidemiol. Biomarkers Prev. 15 (9), 1582 (2005).
   Web of Science ®Google Scholar
• Saunders WB . Specimen collection and processing: sources of biological variation. In : Textbook of Clinical Chemistry. TiezMW ( Ed.). Philadelphia, PA, USA, 478–518 (1986).
   Google Scholar
• Allison RW . Sample collection and handling: getting accurate results. Vet. Clin. North Am. Small Anim. Pract. 37 (2), 203–219 (2007).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Guidance for Industry, Bioanalytical Method Validation. Rockville, MD, USA (2001).
   Google Scholar
• EMA . Committee for Medicinal Products for Human Use (CHMP). Guideline on Bioanalytical Method Validation. EMEA/CHMP/EWP/192217/2009. London, UK (2011).
   Google Scholar
• Japanese Ministry of Health, Labour and Welfare. Guideline on Bioanalytical Method Validation in Pharmaceutical Development. Japan (2013).
   Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Draft Guidance for Industry, Bioanalytical Method Validation. Rockville, MD, USA (2013).
   Google Scholar
• Arnold ME , BoothB, KingL, RayC. Workshop report: Crystal City VI – bioanalytical method validation for biomarkers. AAPS J. doi: 10.1208/s12248-016-9946-6 (2016) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Lee JW , DevanarayanV, BarrettYCet al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23 (2), 312–328 (2006).
   PubMed Web of Science ®Google Scholar
• Hougton R , GoutyD, AllinsonJet al. Recommendations on biomarker bioanalytical method validation by GCC. Bioanalysis4 (20), 2439–2446 (2012).
   PubMed Web of Science ®Google Scholar
• Timmerman P , HerlingC, StoellnerDet al. European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development. Bioanalysis4 (15), 1883–1894 (2012).
   PubMed Web of Science ®Google Scholar
• Bower J , FastD, GarofoloFet al. 8th GCC: Consolidated feedback to US FDA on the 2013 Draft FDA Guidance on Bioanalytical Method Validation. Bioanalysis6 (22), 2957–2963 (2012).
   Web of Science ®Google Scholar
• Rocci M , LowesS, ShoupRet al. 7th GCC Insights: incurred samples use; fit-for-purpose validation, solution stability, electronic laboratory notebook and hyperlipidemic matrix testing. Bioanalysis6 (20), 2713–2720 (2014).
   PubMed Web of Science ®Google Scholar
• Hayes R , LeLacheurR, DumontIet al. 9th GCC closed forum: CAPA in regulated bioanalysis; method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory notebooks. Bioanalysis8 (6), 487–495 (2016).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Veterinary Medicine. Draft Guidance for Industry, Data Integrity and Compliance with CGMP. Rockville, MD, USA (2016).
   Google Scholar
• MHRA GMP Data Integrity Definitions and Guidance for Industry . London, UK (2015).
   Google Scholar
• Song A et al. 2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 – Hybrid LBA/LCMS and input from regulatory agencies). Bioanalysis doi: 10.4155/bio-2016-4988 (2016) ( In Press).
   Web of Science ®Google Scholar
• EMA . Committee for Medicinal Products for Human Use (CHMP). Reflection paper on guidance for laboratories that perform the analysis or evaluation of clinical trial samples. EMA/INS/GCP/532137/2010. London, UK (2012).
   Google Scholar
• ICH Guideline for Good Clinical Practice E6(R1) (1996).
   Google Scholar
• US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research. Guidance for Industry, Safety Testing of Drug Metabolites. Rockville, MD, USA (2008).
   Google Scholar
• Ma S , ChowdhurySK. Data acquisition and data mining techniques for metabolite identification using LC coupled to high-resolution MS. Bioanalysis5 (10), 1285–1297 (2013).
   PubMed Web of Science ®Google Scholar
• Leonart LP , GasparettoJC, PontaroloR. Uncovering previously undetected metabolites using modern bioanalytical tools. Bioanalysis7 (12), 1419–1422 (2015).
   PubMed Web of Science ®Google Scholar
• Bowen CL , KehlerJ, BoramSet al. Modify on the fly: triple quad to high resolution in support of a dermal clinical study requiring an ultra low LLOQ. Bioanalysis8 (3), 205–214 (2016).
   PubMed Web of Science ®Google Scholar
• Sturm RM , JonesBR, MulvanaDE, LowesS. HRMS using a Q-Exactive series mass spectrometer for regulated quantitative bioanalysis: how, when, and why to implement. Bioanalysis8 (16), 1709–1721 (2016).
   PubMed Web of Science ®Google Scholar
• Woolf EJ , McDougallS, FastDMet al. Small molecule specific run acceptance, specific assay operation, and chromatographic run quality assessment: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization teams. AAPS J. 16 (5), 885–893 (2014).
   PubMed Web of Science ®Google Scholar